Drug – bio-affecting and body treating compositions – Plant material or plant extract of undetermined constitution... – Containing or obtained from leguminosae
Reexamination Certificate
2000-11-17
2003-11-04
Griares, Theodore J. (Department: 1617)
Drug, bio-affecting and body treating compositions
Plant material or plant extract of undetermined constitution...
Containing or obtained from leguminosae
C424S401000, C514S844000
Reexamination Certificate
active
06641848
ABSTRACT:
This Application is a 371 of PCT/FR99/01260 filed May 28, 1999, which claims priority to French Application 98/06821 filed May 29, 1998.
The present invention relates in general terms to the use of saponins or sapogenols in cosmetology and for the manufacture of pharmaceutical compositions for treating the skin in order to increase the amount of collagen IV in the dermo-epidermal junction.
It further relates to novel cosmetic or pharmaceutical compositions which promote an increase in the amount of collagen IV in the dermo-epidermal junction, and to a method of cosmetic treatment using a saponin or a sapogenol.
The dermo-epidermal junction is known to be a complex structure which assures the cohesion and exchanges between the dermis and the epidermis which are essential for the skin to function properly.
It is further known that type IV collagen, also called collagen IV, is a major constituent of the dermo-epidermal junction, which is involved especially in maintaining a functional interface between the dermis and the epidermis.
The optimum physiological state of the dermo-epidermal junction depends on there being a sufficient amount of collagen IV in this dermo-epidermal junction.
Therefore, to maintain or restore the physiological state of the dermo-epidermal junction, it is desirable to have a means of increasing the amount of collagen IV therein.
It has been discovered that triterpenic saponins and sapogenols, preferably of type A or type B and especially those which are cosmetically or pharmaceutically acceptable, are particularly appropriate as agents for increasing the amount of collagen IV in the dermo-epidermal junction; it is this discovery which constitutes the basis of the present invention.
Thus, according to a first feature, the present patent application aims to cover the use of at least one cosmetically acceptable saponin or sapogenol of triterpenic character, particularly a saponin or sapogenol extracted from a plant, preferably from soya or a plant of the Medicago type, or of a plant extract rich in such compounds, as a cosmetic agent for increasing the amount of collagen IV in the dermo-epidermal junction.
As well as the cosmetic field, the invention is also applicable in the pharmaceutical field, especially the dermatological field.
Thus, according to a second feature, the present patent application aims to cover the use of at least one pharmaceutically acceptable saponin or sapogenol of triterpenic character, particularly a saponin or sapogenol extracted from a plant, preferably from soya or a plant of the Medicago type, or of a plant extract rich in such compounds, for the manufacture of a pharmaceutical composition, especially dermatological composition, for treating pathological conditions associated with a deficiency of the dermo-epidermal junction resulting from an insufficient amount of collagen IV.
A very large number of saponins and sapogenols of triterpenic character are found to be appropriate within the framework of the use according to the present invention, in the cosmetic or pharmaceutical field.
These compounds, which will have to be cosmetically or pharmaceutically acceptable within the framework of a cosmetic or pharmaceutical use, will advantageously be extracted from plants. They could also be obtained by chemical synthesis, as is easily comprehensible and known to those skilled in the art.
In particular, it will be possible to use saponins extracted from plants, preferably those extracted from
Glycine max
(soya),
Phaseolus vulgaris, Phaseolus aureus, Phaseolus lunatus, Vicia faba, Lens culinaris, Cicer arietum, Vigna angularis, Vigna mungo, Oxytropis ochrocephala, Oxytropis glabra, Pisum sativum, Sophora favescens, Asparalus membranaceus, Crotalaria albida, Arachis hypogea, Galega officinalis, Wistaria brachybotrys
and
Trifolium repens
, or those extracted from plants of the Medicago type, particularly
Medicago alfalfa
and
Medicago sativa
, which is often called “alfalfa”.
According to a third feature, the present patent application aims to cover the use of at least one saponin or sapogenol extracted from a plant rich in such compounds and selected from
Glycine max
(soya),
Phaseolus vulgaris, Phaseolus aureus, Phaseolus lunatus, Vicia faba, Lens culinaris, Cicer arietum, Vigna angularis, Vigna mungo, Oxytropis ochrocephala, Oxytropis glabra, Pisum sativum, Sophora favescens, Asparalus membranaceus, Crotalaria albida, Arachis hypogea, Galega officinalis, Wistaria brachybotrys
and
Trifolium repens
, or a plant of the Medicago type, particularly
Medicago alfalfa
and
Medicago sativa
, or “alfalfa”, as a cosmetic agent for increasing the amount of collagen IV in the dermo-epidermal junction.
According to a fourth feature, the present invention aims to cover the use of at least one saponin or sapogenol extracted from a plant rich in such compounds and selected from
Glycine max
(soya),
Phaseolus vulgaris, Phaseolus aureus, Phaseolus lunatus, Vicia faba, Lens culinaris, Cicer arietum, Vigna angularis, Vigna mungo, Oxytropis ochrocephala, Oxytropis glabra, Pisum sativum, Sophora favescens, Asparalus membranaceus, Crotalaria albida, Arachis hypogea, Galega officinalis, Wistaria brachybotrys
and
Trifolium repens
, or a plant of the Medicago type, particularly
Medicago alfalfa
and
Medicago sativa
, or “alfalfa”, for the manufacture of a pharmaceutical composition, especially dermatological composition, for treating pathological conditions associated with a deficiency of the dermo-epidermal junction resulting from an insufficient amount of collagen IV.
Soya and plants of the Medicago type, such as
Medicago sativa
, are particularly appropriate plants for providing saponins or sapogenols which can be used within the framework of the invention, since said compounds are of the triterpenic type and, in particular, of type A or type B.
These saponins or sapogenols of triterpenic character will advantageously comprise type A or type B triterpenic soya saponins or soya sapogenols and may be extracted in particular from a plant of the Medicago type, such as
Medicago alfalfa
and
Medicago sativa.
These type A or type B triterpenic soya saponins or soya sapogenols are well known in the literature (cf. on the one hand the article by Georges Massiot, Catherine Lavaud, Dominique Guillaume and Louisette Le Men-Olivier in J. Agric. Food Chem. (1988), 36, pages 902-909, and on the other hand the book entitled “Saponins” by Hostettman K. and Marston A. (1995), published by Cambridge University Press, particularly Appendix 2, references 446 to 460 and 517 to 519. They have the following chemical formulae:
type A soya sapogenol
type B soya sapogenol
Sapogenols do not contain a sugar substituent, so they are generally called aglycones. On the other hand, they can be substituted by sugars or sugar chains and are then called soya saponins, which can thus be of type A or type B.
The following may be mentioned as examples:
Soya sapogenol A. aglycone
(according to Appendix 2 of Hostettman and Marston
(1995) - Cambridge University Press)
Bibliographic
Name
Structure
Plant extracted
reference
No. 517
3-GlcA
2
-Gal
Glycine max
Kitagawa et al.
Soya saponin A
2
22-Ara
3
-Glc
(Leguminosae)
1985c
No. 518
3-GlcA
2
-Gal
2
-Glc
Glycine max
Kitagawa et al.
Soya saponin A
1
22-Ara
3
-Glc
(Leguminosae)
1985a
No. 519
3-GlcA
2
-Gal
2
-Rha
Glycine max
Curl et al.
Soya saponin A
3
(Leguminosae)
1988b
Soya sapogenol B. aglycone
(according to Appendix 2 of Hostettman and Marston
(1995) - Cambridge University Press)
Bibliographic
Name
Structure
Plant extracted
reference
No. 446
24-Glc
Phaseolus
Jain et al. 1988
vulgaris
(Leguminosae)
No. 447
3-GlcA
2
-Ara
Glycine max
Burrows et al.
Soya saponin
(Leguminosae)
1987
IV
No. 448
3-GlcA
2
-Gal
G. max
Kitagawa et al.
Soya saponin
(Leguminosae)
1982
III
No. 449
3-GlcA
2
-Glc
Vigna angularis
Kitagawa et al.
Azuki saponin
(Leguminosae)
1983c
II
Medicago sativa
Kitagawa et al.
(Leguminosae)
1988d
No. 450
3-Glc
4
-Glc
Phaseolus
Jain et al. 1991
Phaseoluside A
½3
vulgaris
Glc
(Leguminosae)
No. 451
3-GlcA
2
-Ara
2
-Rha
Bonte Frederic
Dumas Marc
Perrier Pierre
Griares Theodore J.
Parfums Christian Dior
Smith , Gambrell & Russell, LLP
Wells Lauren Q.
LandOfFree
Saponin or sapogenol compositions for increasing collagen IV... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Saponin or sapogenol compositions for increasing collagen IV..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Saponin or sapogenol compositions for increasing collagen IV... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3124612